Vivos Therapeutics
VVOS
37 hedge funds and large institutions have $9.14M invested in Vivos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 9 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
28% more funds holding
Funds holding: 29 → 37 (+8)
24% more call options, than puts
Call options by funds: $707K | Put options by funds: $568K
0.01% less ownership
Funds ownership: 0.41% → 0.4% (-0.01%)
22% less capital invested
Capital invested by funds: $11.7M → $9.14M (-$2.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$981K |
| 2 |
Two Sigma Investments
New York
|
+$661K |
| 3 |
AIA
Avalon Investment & Advisory
Houston,
Texas
|
+$587K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$333K |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$1.72M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$1.11M |
| 3 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$1.06M |
| 4 |
Walleye Capital
New York
|
-$743K |
| 5 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$465K |
VVOS Hedge Fund Activity: Q3 2021 in Review
37 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2021, worth a combined $9.14M — down 22% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new VVOS positions and 9 closed out — a net gain of 8 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $981K. The largest seller was Royce & Associates, exiting entirely with an estimated $1.72M sold.
- 37 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2021, up from 29 in Q2 2021.
- Funds reported $9.14M of Vivos Therapeutics stock for Q3 2021, down 22% quarter-over-quarter.
- 17 funds opened new Vivos Therapeutics positions in Q3 2021 and 9 closed out, a net change of +8 holders.
- The largest Vivos Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $981K added.
- The largest Vivos Therapeutics seller in Q3 2021 was Royce & Associates, an estimated $1.72M sold.
Based on aggregated 13F filings for Q3 2021.